Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics dev...
To acquire biologics manufacturing facility and capabilities from XOMAAcquires rights to Selexis cell line development technology. Purchases an exclusive license to a Phage Display library from Iontas